Vivek Subbiah: Thrilled to have had Jason Dorsey as the keynote speaker at the Sarah Cannon Research Institute 27th Annual Scientific event shedding light on the generational divide
Vivek Subbiah recently shared a post by Jason Dorsey, President – Researcher at on on LinkedIn, adding:
“Thrilled to have had Jason Dorsey as the keynote speaker at the Sarah Cannon Research Institute 27th Annual Scientific event, Nashville Tennessee, shedding light on the generational divide.
Jason Dorsey’s forward-looking keynote was not only energetic but also a phenomenal lecture, captivating the entire audience.
Jason Dorsey’s insights were a definite highlight of the event, sparking engaging conversations and inspiring us to consider the future with fresh perspectives. Grateful for the enriching experience!”
Quoting Jason Dorsey’s post:
“I love speaking to leaders who are saving lives and helping families every day—which is precisely what Sarah Cannon Research Institute does! It was a huge honor to speak to their leaders from across the US and UK.
I am immensely grateful for the response and standing ovation! These leaders are pioneering breakthroughs that save lives and advance medical care. I’m deeply grateful to each of them and their visionary leadership.
VERY BIG h/t to Vivek, Dee Anna, Skip, and David for the breakthrough work they lead and for organizing an exceptional summit.
I’ll write a full post later this week, but for now I just want to highlight this incredible organization and its inspiring leaders. Thank YOU for what you do.”
Source: Vivek Subbiah/LinkedIn and Jason Dorsey/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor-agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.